[Prognostic value of estradiol and progesterone receptors in stage I and II breast cancer with an adjuvant treatment]. 1987

M Bolla, and P Bonnabel, and M Chedin, and D Villemain, and M Zins, and M Mousseau, and E Chambaz
Service de Radiothérapie, CHU de Grenoble, France.

Forty-seven stage T1, 225 stage T2, treated from January 1977 to December 1982 were studied. The median followup is 31 months (18-92) and the median age 57.5 years (26-92). On the 247 axillary clearances performed, there were 53% N- and 47% N+. The dextran coal method was used for the receptors dosage with R 2858 as ligand for estradiol and R 5020 for progesterone: positivity threshold was set at 10 fmoles. The RE+/RP+ group represents 40%, the RE+/RP- group 30%, the RE-/RP- group 7%, the RE-/RP- group 23%. The radio-surgical combination was systematic, with or without conservative treatment, followed by an adjuvant chemotherapy (15%), an hormonotherapy (34%), a chemohormonoprophylaxy (23%), within a protocol balancing the systemic treatment according to the following poor prognosis factors: axillary clearance positivity, grade 3 SBR, cytological grade 3. The crude actuarial survival is 96 +/- 4% (RE+ RP+); 73 +/- 15% (RE+ RP-); 78 +/- 12% (RE- RP-) and the disease-free survival was 84 +/- 9% (RE+ RP+); 68 +/- 15% (RE+ RP-), 67 +/- 14% (RE- RP-) with a significant difference between RE+ RP+ and RE+ RP- (P less than 10(-3)) and RE+ RP+ and RE- RP- (P less than 10(-5)). The crude actuarial survival and the disease free survival are studied according to menopausal status, Scarff-Bloom grade, and N+/N- axillary status. For N- patients, there is no significant difference for the disease-free survival, 84 +/- 14% (RE+ RP+); 85 +/- 11% (RE+ RP-); 79 +/- 15% (RE- RP-), as there is no difference for the five year disease-free survival between N- RE+ RP+ patients (84 +/- 14%) and N+ RE+ RP+ patients (84 +/- 13%).

UI MeSH Term Description Entries
D008207 Lymphatic Metastasis Transfer of a neoplasm from its primary site to lymph nodes or to distant parts of the body by way of the lymphatic system. Lymph Node Metastasis,Lymph Node Metastases,Lymphatic Metastases,Metastasis, Lymph Node
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009367 Neoplasm Staging Methods which attempt to express in replicable terms the extent of the neoplasm in the patient. Cancer Staging,Staging, Neoplasm,Tumor Staging,TNM Classification,TNM Staging,TNM Staging System,Classification, TNM,Classifications, TNM,Staging System, TNM,Staging Systems, TNM,Staging, Cancer,Staging, TNM,Staging, Tumor,System, TNM Staging,Systems, TNM Staging,TNM Classifications,TNM Staging Systems
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D011959 Receptors, Estradiol Cytoplasmic proteins that bind estradiol, migrate to the nucleus, and regulate DNA transcription. Estradiol Receptors,Estradiol Receptor,Receptor, Estradiol
D011960 Receptors, Estrogen Cytoplasmic proteins that bind estrogens and migrate to the nucleus where they regulate DNA transcription. Evaluation of the state of estrogen receptors in breast cancer patients has become clinically important. Estrogen Receptor,Estrogen Receptors,Estrogen Nuclear Receptor,Estrogen Receptor Type I,Estrogen Receptor Type II,Estrogen Receptors Type I,Estrogen Receptors Type II,Receptor, Estrogen Nuclear,Receptors, Estrogen, Type I,Receptors, Estrogen, Type II,Nuclear Receptor, Estrogen,Receptor, Estrogen
D011980 Receptors, Progesterone Specific proteins found in or on cells of progesterone target tissues that specifically combine with progesterone. The cytosol progesterone-receptor complex then associates with the nucleic acids to initiate protein synthesis. There are two kinds of progesterone receptors, A and B. Both are induced by estrogen and have short half-lives. Progesterone Receptors,Progestin Receptor,Progestin Receptors,Receptor, Progesterone,Receptors, Progestin,Progesterone Receptor,Receptor, Progestin
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D005260 Female Females

Related Publications

M Bolla, and P Bonnabel, and M Chedin, and D Villemain, and M Zins, and M Mousseau, and E Chambaz
January 1985, Breast cancer research and treatment,
M Bolla, and P Bonnabel, and M Chedin, and D Villemain, and M Zins, and M Mousseau, and E Chambaz
April 1988, Journal of surgical oncology,
M Bolla, and P Bonnabel, and M Chedin, and D Villemain, and M Zins, and M Mousseau, and E Chambaz
December 1983, The New England journal of medicine,
M Bolla, and P Bonnabel, and M Chedin, and D Villemain, and M Zins, and M Mousseau, and E Chambaz
May 1984, The New England journal of medicine,
M Bolla, and P Bonnabel, and M Chedin, and D Villemain, and M Zins, and M Mousseau, and E Chambaz
January 1984, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer,
M Bolla, and P Bonnabel, and M Chedin, and D Villemain, and M Zins, and M Mousseau, and E Chambaz
January 1997, Neoplasma,
M Bolla, and P Bonnabel, and M Chedin, and D Villemain, and M Zins, and M Mousseau, and E Chambaz
January 1987, Archivos de investigacion medica,
M Bolla, and P Bonnabel, and M Chedin, and D Villemain, and M Zins, and M Mousseau, and E Chambaz
January 1983, Breast cancer research and treatment,
M Bolla, and P Bonnabel, and M Chedin, and D Villemain, and M Zins, and M Mousseau, and E Chambaz
January 1984, La semaine des hopitaux : organe fonde par l'Association d'enseignement medical des hopitaux de Paris,
M Bolla, and P Bonnabel, and M Chedin, and D Villemain, and M Zins, and M Mousseau, and E Chambaz
January 1985, Neoplasma,
Copied contents to your clipboard!